• Je něco špatně v tomto záznamu ?

Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver

Ľ. Pašková, V. Kuncírová, S. Poništ, D. Mihálová, R. Nosáľ, J. Harmatha, I. Hrádková, T. Čavojský, F. Bilka, K. Šišková, I. Paulíková, L. Bezáková, K. Bauerová,

. 2016 ; 2016 (-) : 7509653. [pub] 20160731

Jazyk angličtina Země Egypt

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013574

Rheumatoid arthritis (RA) is a chronic inflammatory disease, leading to progressive destruction of joints and extra-articular tissues, including organs such as liver and spleen. The purpose of this study was to compare the effects of a potential immunomodulator, natural polyphenol N-feruloylserotonin (N-f-5HT), with methotrexate (MTX), the standard in RA therapy, in the chronic phase of adjuvant-induced arthritis (AA) in male Lewis rats. The experiment included healthy controls (CO), arthritic animals (AA), AA given N-f-5HT (AA-N-f-5HT), and AA given MTX (AA-MTX). N-f-5HT did not affect the body weight change and clinical parameters until the 14th experimental day. Its positive effect was rising during the 28-day experiment, indicating a delayed onset of N-f-5HT action. Administration of either N-f-5HT or MTX caused reduction of inflammation measured as the level of CRP in plasma and the activity of LOX in the liver. mRNA transcription of TNF-α and iNOS in the liver was significantly attenuated in both MTX and N-f-5HT treated groups of arthritic rats. Interestingly, in contrast to MTX, N-f-5HT significantly lowered the level of IL-1β in plasma and IL-1β mRNA expression in the liver and spleen of arthritic rats. This speaks for future investigations of N-f-5HT as an agent in the treatment of RA in combination therapy with MTX.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013574
003      
CZ-PrNML
005      
20240312143739.0
007      
ta
008      
170413e20160731ua f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2016/7509653 $2 doi
035    __
$a (PubMed)27556049
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ua
100    1_
$a Pašková, Ľudmila $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia.
245    10
$a Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver / $c Ľ. Pašková, V. Kuncírová, S. Poništ, D. Mihálová, R. Nosáľ, J. Harmatha, I. Hrádková, T. Čavojský, F. Bilka, K. Šišková, I. Paulíková, L. Bezáková, K. Bauerová,
520    9_
$a Rheumatoid arthritis (RA) is a chronic inflammatory disease, leading to progressive destruction of joints and extra-articular tissues, including organs such as liver and spleen. The purpose of this study was to compare the effects of a potential immunomodulator, natural polyphenol N-feruloylserotonin (N-f-5HT), with methotrexate (MTX), the standard in RA therapy, in the chronic phase of adjuvant-induced arthritis (AA) in male Lewis rats. The experiment included healthy controls (CO), arthritic animals (AA), AA given N-f-5HT (AA-N-f-5HT), and AA given MTX (AA-MTX). N-f-5HT did not affect the body weight change and clinical parameters until the 14th experimental day. Its positive effect was rising during the 28-day experiment, indicating a delayed onset of N-f-5HT action. Administration of either N-f-5HT or MTX caused reduction of inflammation measured as the level of CRP in plasma and the activity of LOX in the liver. mRNA transcription of TNF-α and iNOS in the liver was significantly attenuated in both MTX and N-f-5HT treated groups of arthritic rats. Interestingly, in contrast to MTX, N-f-5HT significantly lowered the level of IL-1β in plasma and IL-1β mRNA expression in the liver and spleen of arthritic rats. This speaks for future investigations of N-f-5HT as an agent in the treatment of RA in combination therapy with MTX.
650    _2
$a zvířata $7 D000818
650    _2
$a arachidonátlipoxygenasy $x genetika $x metabolismus $7 D001091
650    _2
$a artritida experimentální $x farmakoterapie $x genetika $x patologie $7 D001169
650    _2
$a biologické markery $7 D015415
650    _2
$a C-reaktivní protein $7 D002097
650    _2
$a cytokiny $x krev $x genetika $x metabolismus $7 D016207
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    12
$a mediátory zánětu $7 D018836
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x farmakologie $7 D008727
650    _2
$a orgánová specificita $7 D009928
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a serotonin $x analogy a deriváty $x farmakologie $7 D012701
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    12
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kuncírová, Viera $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
700    1_
$a Poništ, Silvester $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
700    1_
$a Mihálová, Danica $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
700    1_
$a Nosáľ, Radomír $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
700    1_
$a Harmatha, Juraj $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 166 10 Prague, Czech Republic.
700    1_
$a Hrádková, Iveta $u Faculty of Food and Biochemical Technology, University of Chemistry and Technology, 166 28 Prague, Czech Republic.
700    1_
$a Čavojský, Tomáš $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia.
700    1_
$a Bilka, František $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia.
700    1_
$a Šišková, Katarína $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia. $7 xx0222712
700    1_
$a Paulíková, Ingrid $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia.
700    1_
$a Bezáková, Lýdia $u Department of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia.
700    1_
$a Bauerová, Katarína, $d 1961- $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia; Department of Galenic Pharmacy, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia. $7 xx0267301
773    0_
$w MED00186351 $t Journal of immunology research $x 2314-7156 $g Roč. 2016 (20160731), s. 7509653
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27556049 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20240312143735 $b ABA008
999    __
$a ok $b bmc $g 1200039 $s 974352
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 2016 $c - $d 7509653 $e 20160731 $i 2314-7156 $m Journal of immunology research $n J. immunol. res. $x MED00186351
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace